Document:

exv10w8

 

Exhibit
10.8

PROMISSORY NOTE

	 	 	 
	$500,000.00

	 	Los Angeles, California
	 

	 	June 30, 2006

FOR VALUE RECEIVED, the undersigned (“Maker”) promises to pay to American Stem Cell
Corporation (“Payee”), or order, at 11300 West Olympic Blvd., Suite 800, Attn: Christopher
Dieterich, or at any other place that Payee designates by notice to Maker, in United States
Dollars, the sum of Five Hundred Thousand dollars ($500.000.00) on the following terms.

1. Payments.

(a) Principal. Subject to the provisions of Section 2, the entire principal amount
hereof shall be payable in full on June 30, 2007 (the “Maturity Date”). No interest shall accrue
prior to maturity.

(b) Prepayments. This Note may be prepaid in whole or in part, at any time prior to
maturity without consent of the holder without any penalty or premium.

2.  Early Repayment.

(a) Upon Closing of a Qualifying Financing. Upon the consummation of the Payee’s
placement of $2,000,000 or more in equity financing prior to the Maturity Date, Maker shall make
partial early repayment of this Note in an amount equal to 10% of such financing up to the amount
of $500,000; provided that if such financing is part of a larger financing with multiple closings,
no payment hereunder shall be due until the final closing of such financing or the Maturity Date,
whichever comes first.

3. Default.

(a) Events of Default. Maker shall be in default of this Note on the occurrence of
any of the following:

(i) Payments. Failure of Maker to make any payment under this Note within three days
of the due date.

(ii) Bankruptcy.

(A) The filing by Maker of a voluntary petition in bankruptcy, a petition for reorganization,
arrangement or other relief under the United States Bankruptcy Act, or a voluntary petition for the
appointment of a receiver or comparable relief from creditors under the laws of any state, or the
making by Maker of an assignment of all or substantially all of its assets for the benefit of
creditors.

(B) The adjudication of Maker as a bankrupt or insolvent, the appointment of a receiver of all
or substantially all of Maker’s assets, or the entry of an order of the reorganization of Maker
under the United States Bankruptcy Act, if such
adjudication, appointment or order is made on a petition filed against Maker and is not,
within 90 days after it is made, vacated or stayed on appeal or otherwise, or if Maker consents to
the appointment, order or petition.

 

 

 

(b) Acceleration on Default. When Maker is in default, the entire unpaid principal
balance of this Note shall become immediately due and payable at the election of Payee, upon the
notification of such election to Maker and the expiration of any applicable cure period, and
interest shall accrue thereafter on the unpaid balance at the rate of 8% per annum.

4. Collection Costs. On any default by Maker, Payee shall be entitled to recover from
Maker all costs of collection and enforcement, including, without limitation, reasonable attorneys’
fees.

5. Condition of Payment. Payment under this Note is conditioned upon the absence of
breach by the ASC Parties under the Final Settlement Agreement, dated as of June 30, 2006, between
the ASC Parties and the Lifeline Parties (the “Settlement Agreement”), the terms of which are
hereby incorporated by reference. Payments to be made under this Note may be offset against any
amounts owed to Maker under the Settlement Agreement at the election of Maker.

6. Remedies Cumulative. The rights and remedies of Payee under this Note are
cumulative and may be pursued singly, successively or together against Maker and any funds or
security held by Payee.

7. Governing Law. This Note and the rights and obligations of the parties hereto
shall be governed by and construed and enforced in accordance with the laws of the State of
California applicable to agreements executed and to be performed in the State of California,
irrespective of its choice-of-law provisions.

8. Notices. Unless otherwise expressly stated in this Note, all notices given
hereunder shall be in writing and shall be served personally, or be mailed in U.S. mail, first
class certified, registered or Express Mail postage prepaid, and a return receipt requested, or be
deposited with a nationally recognized commercial courier service with next-day delivery charges
prepaid. Notices may also effectively be given by transmittal over facsimile machine or other
electronic transmitting device if the party to whom the notice is being sent has a receiving device
in its office and a copy of the notice is also served personally or in the same manner required for
a mailed notice or a notice deposited with a commercial courier service. Notices shall be deemed
received at the earlier of actual receipt or three days following deposit, in the manner required
above, in U.S. mail or with a commercial courier service. Notices shall be directed to the
following addresses:

	 	 	 	 	 
	 

	 	Payee:
	 	American Stem Cell Corporation
	 

	 	 	 	C/O Christopher Dieterich
	 

	 	 	 	11300 W. Olympic Blvd. Suite 800
	 

	 	 	 	Los Angeles, CA 90064

 

2

 

	 	 	 	 	 
	 

	 	Maker:
	 	Lifeline Cell Technology, LLC
	 

	 	 	 	157 Surfview Drive
	 

	 	 	 	Pacific Palisades, CA 90272

Either party to this Note may change its address for notice purposes by giving notice to the other
parties in accordance with this Section 7, provided that the address change shall not be effective
until three days after notice of the change.

9. Severability. If any part of this Note is determined to be illegal or
unenforceable, all other parts shall remain in effect.

10. Successors and Assigns. This Note shall inure to the benefit of and bind the
parties hereto and their respective successors, assigns, heirs, executors and administrators.

IN WITNESS WHEREOF, Maker has signed and delivered this Note effective as of the date first
set forth above.

Lifeline Cell Technology, LLC

By:/S/ KENNETH C. ALDRICH

Accecpted: American Stem Cell Corporation

By:          /S/KENNETH SWAISLAND

 

3exv10w9

 

Exhibit 10.9

FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (ACT IP)

This First Amendment to Exclusive License Agreement (ACT IP) (“First Amendment”) is made and
entered into as of this 1ST day of August, 2005 (the “Amendment Effective Date”), by and between
Advanced Cell, Inc. (formerly known as Advanced Cell Technology, Inc.), a Delaware corporation with
offices located at 381 Plantation Street, Worcester, Massachusetts 01605 (“LICENSOR”), and Lifeline
Cell Technology, LLC (formerly known as PacGen Cellco, LLC), a California limited liability company
with offices located at 157 Surfview Drive, Pacific Palisades, CA 90272 (“LICENSEE”) (LICENSOR and
LICENSEE sometimes hereinafter referred to individually as a “Party” and collectively as the
“Parties”).

WHEREAS, the Parties previously entered into an Exclusive License Agreement (ACT IP), dated
May 14, 2004 (the “License Agreement”), which grants LICENSEE defined rights to use certain
intellectual property controlled by LICENSOR; and

WHEREAS, the Parties also entered into that certain Agreement to Amend ACT/Cellco License
Agreements dated September 7, 2004 (the “Agreement to Amend”), which contemplates that the Parties
will amend the License Agreement in certain respects; and

WHEREAS, the Parties have agreed to amend the License Agreement as provided herein;

NOW, THEREFORE, in consideration of the premises and terms of this First Amendment, and in
consideration of the payment to LICENSOR by LICENSEE of $84,375, the receipt of which is hereby
acknowledged by LICENSOR, the Parties agree to amend the License Agreement as follows:

1. Section 1.2 is deleted in its entirety and replaced with the following:

	 	1.2	 	“FIELD” shall mean (1) the research, development, manufacture and selling to
third parties of human and non-human animal cells for commercial research use,
including small molecule and other drug testing and basic research and (2) the
manufacture and selling of human cells for therapeutic and diagnostic use in the
treatment of human (a) diabetes, (b) liver diseases and (c) retinal diseases and
retinal degenerative diseases; but FIELD shall exclude applications involving the use
of cells in the treatment of tumors where the primary use of the cells is the
destruction or reduction of tumors and does not involve regeneration of tissue or organ
function.

2. Section 1.3 is deleted in its entirety and replaced with the following:

	 	1.3	 	“KNOW-HOW” means all compositions of matter, techniques and data and other
know-how and technical inventions (whether or not patentable), improvements and
developments, practices, methods, concepts, trade secrets, documents, computer data,
computer code, apparatus, clinical and regulatory strategies, test data, analytical and
quality control data, formulation, manufacturing, patent data or descriptions,
development information, drawings, specifications, designs, plans, proposals and
technical data and manuals and all other proprietary

 

 

 

	 	 	 	information that is owned or controlled by LICENSOR as of the Effective Date that
relates to cloning technology or to any of the subject matter described in or
claimed by the PATENT RIGHTS and is relevant to the FIELD. By way of illustration,
but not in limitation, KNOW-HOW shall include commercial rights in the FIELD to any
existing or potential research products, including reagents, developed by LICENSOR
in the course of its in-house research as more fully described in Section 15.3 of
this Agreement. An example of this is the proprietary culture medium developed by
LICENSOR in the course of the development of LICENSOR’s proprietary ooplasmic
transfer technology.

3. Section 1.9 is amended by deleting the text in Section 1.9 in its entirety and replacing it with
the following: “Intentionally omitted”.

4. Section 2.5 is deleted in its entirety and replaced with the following:

LICENSEE acknowledges and agrees that notwithstanding anything to the contrary in
this Agreement, LICENSOR may: (i) practice the LICENSED TECHNOLOGY and develop and
manufacture LICENSED PRODUCTS within the FIELD for research purposes, provided that
LICENSOR may not market or sell LICENSED PRODUCTS in the FIELD to third parties in
contravention of LICENSEE’S exclusive rights hereunder; (ii) distribute or otherwise
transfer cells or cell lines or other reagents to collaborators for research
purposes, and commercialize the results of such research (other than media and other
reagents produced for sale to the commercial research market) outside the FIELD in
connection with the research, development, manufacture or sale of therapeutic
products that are not in contravention of LICENSEE’S exclusive rights hereunder; and
(iii) distribute or otherwise transfer cells or cell lines to collaborators for the
purposes of researching, developing and commercializing cell based therapeutics for
purposes other than those exclusively licensed to LICENSEE hereunder.

By way of illustration of subparagraph (ii) of Section 2.5 hereof, should
LICENSOR partner with a biopharmaceutical company in order to produce skin
cells for human therapeutic use, and in the process of basic research,
preclinical, or clinical development find it necessary or useful to transfer
cell lines or other reagents to that partner to facilitate the development
of such dermatological product, such transfer, provided that the transferred
material is not sold or marketed to such biopharmaceutical company for
monetary compensation, shall be considered outside of the FIELD.

LICENSOR may make LICENSED PRODUCTS available to its collaborators. In the
event LICENSOR requests that LICENSEE deliver to LICENSOR LICENSED PRODUCTS
in the FIELD for use in connection with the purposes described in the above
paragraph, LICENSEE shall make such LICENSED PRODUCTS available to LICENSOR
on commercially reasonable terms. LICENSOR may make

 

2

 

LICENSED PRODUCTS in the FIELD, whether developed and manufactured by
LICENSOR or obtained from LICENSEE, available to its collaborators, provided
that LICENSOR enters into a license with any such collaborator that
expressly prohibits the collaborator from commercializing the LICENSED
TECHNOLOGY in the FIELD or using the LICENSED PRODUCTS in the FIELD for any
purpose other than in connection with the collaboration with LICENSOR for
the purposes described above. LICENSOR shall provide LICENSEE with a copy
of any such license entered into with a collaborator prior to delivering any
LICENSED PRODUCTS in the FIELD; provided, however, that
LICENSOR may redact from such license agreements any financial terms
LICENSOR considers proprietary or confidential and not relevant to
LICENSEE’S exclusive rights hereunder, and provided further that any
such licenses provided to LICENSEE shall be considered and treated as
Confidential Information under Article 10 of this Agreement. Any license by
LICENSOR to a collaborator hereunder shall specifically provide that any
intellectual property developed under such collaboration shall be treated as
if developed by LICENSOR for purposes of determining if it is subject to any
of the provisions of this Agreement.

5. Section 2.6 is deleted in its entirety.

6. Section 4.3 is amended in part by deleting the text (including numbers) after the words “and the
following minimum amounts:” and replacing such text with the following:

	 	 	 	 	 
	 

	 	(i)
	 	At 12 months, $15,000
	 

	 	(ii)
	 	At 24 months, $37,500
	 

	 	(iii)
	 	At 36 months, $60,625
	 

	 	(iv)
	 	Annually thereafter, $75,000

7. Section 15.3 is amended by deleting the words “including any rights acquired under Section 15.18
hereof,”.

8. Section 15.18 is amended by deleting the text in said Section in its entirety and replacing it
with the following:

	 	15.18	 	To support the grant of rights hereunder with respect to retinal disease,
LICENSOR shall provide the services of Robert Lanza, M.D., his assistants and the use
of such lab space and equipment as they may need that LICENSOR can reasonable supply,
understanding that Dr. Lanza, his assistants are the full-time employees of LICENSOR
and the equipment will be primarily used for LICENSOR research. Such assistance will be
for a period of the earlier of one year from the date of this Amendment or until:

(a) the completion of preliminary animal studies to assess safety and
efficacy of applying cells for the treatment of retinitis pigmentosa and/or
macular degeneration (including any contracts or rights already
established for initial animal studies);

 

3

 

(b) completion and submission of a scientific paper to a peer-reviewed
journal co-authored by LICENSOR and LICENSEE scientists presenting animal
data and analysis (subject to the pre-approval of both parties prior to
publication);

(c) completion of consultations with the FDA to assess the suitability of
animal data gathered to initiate the paperwork for early stage human
clinical trials;

(d) initiation of process of filing the paperwork for early stage human
trials.

A committee composed of Michael West, Ph.D., Robert Lanza, M.D. and Irina
Klimanskaya, Ph.D., as the LICENSOR representatives, and Jeffrey Janus and two
additional representatives from LICENSEE that LICENSEE will promptly identify to
LICENSOR in writing (the “Committee”), will meet periodically during the six-month
period commencing on the Amendment Effective Date to discuss completion of the
above-identified tasks.

The LICENSEE Committee representatives may consult informally with the LICENSOR
Committee representatives, both in person and by telephone, regarding issues of
mutual interest identified by the Committee. The Committee shall meet during such
six-month period at the facilities of LICENSOR or LICENSEE as shall be mutually
determined; the time and place of such meetings, and the agenda for such meetings,
shall be determined by mutual agreement. It is contemplated by the Parties that the
Committee will meet three times during the six-month period. Either party may
replace its representatives at any time, upon written notice and mutual agreement of
the parties.

The foregoing notwithstanding, if LICENSOR is unable or unwilling to complete the
tasks outlined in this Section 15.18 above, LICENSEE shall have the right to manage
and carry the work forward so long as LICENSEE provides funding for the project, in
which case any intellectual property that is developed under LICENSEE’s management
and funding shall accrue to LICENSEE, and LICENSEE shall be entitled to treat as
prepayment of future licensing requirements under this and other license agreements
between LICENSOR and LICENSEE the actual costs incurred by LICENSEE in completing
subsections (a) through (d) above; provided, however, that LICENSEE
shall not be entitled to treat any such costs as prepayment of future licensing
requirements under this and other license agreements between LICENSOR and LICENSEE
if LICENSOR transfers to LICENSEE the technological protocols, techniques and
training necessary for LICENSEE to replicate LICENSOR’S generation of retinal cells
from stem cells. LICENSEE and LICENSOR agree that the transfer to LICENSEE of the
technological protocols, techniques and training necessary for LICENSEE to replicate
LICENSOR’S generation of retinal cells from stem cells
shall be complete when LICENSOR provides LICENSEE with written copies of such
protocols and techniques and two weeks of additional lab training at the Worcester
facility by two qualified technicians within six months after the Amendment
Effective Date.

 

4

 

9. The Agreement is amended by replacing all references to the word “Product” with the term
“Licensed Product”.

10. This First Amendment shall be governed by and construed in accordance with the laws of the
State of Delaware, without regard to principles of conflicts of law thereof, and shall be binding
upon and inure to the benefit of the Parties and their respective successors and assigns.

11. The Parties agree that the Agreement to Amend is terminated by mutual agreement and that all of
its provisions are superseded in their entirety by this First Amendment. The License Agreement, as
amended hereby, contains the entire agreement of the Parties hereto and thereto with respect to the
matters discussed herein and therein. This First Amendment may not be modified except in writing
signed by the Parties.

12. Except to the extent specifically amended hereby, the terms and provisions of the License
Agreement are hereby ratified and affirmed in all respects and continue in full force and effect.

IN WITNESS WHEREOF, this First Amendment has been executed by duly authorized representatives
of the Parties as of the Amendment Effective Date.

ADVANCED CELL, INC.

By: /S/ WILLIAM M. CALDWELL, IV

Printed Name: William M. Caldwell, IV

Title: Chief Executive Officer

LIFELINE CELL TECHNOLOGY, LLC

By: /S/ KENNETH ALDRICH

Printed Name: Kenneth Aldrich

Title: Managing Member

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}]]